NEOGENOMICS INC
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $727.3M | $660.6M | $591.6M | $509.7M | $484.3M |
| Cost of revenue | $413.0M | $370.5M | $347.0M | $321.8M | $297.3M |
| Gross profit | $314.3M | $290.1M | $244.6M | $187.9M | $187.1M |
| Research and development | $37.1M | $31.2M | $27.3M | $30.3M | $21.9M |
| Operating expenses | $430.2M | $382.2M | $352.3M | $345.5M | $305.8M |
| Operating income | -$115.9M | -$92.1M | -$107.7M | -$157.6M | -$118.8M |
| Interest expense | $3.8M | $6.6M | $6.9M | $7.6M | $8.2M |
| Pretax income | -$110.3M | -$80.7M | -$97.1M | -$159.3M | -$15.1M |
| Income tax expense | -$2.2M | -$1.9M | -$9.1M | -$15.1M | -$6.7M |
| Net income | -$108.0M | -$78.7M | -$88.0M | -$144.2M | -$8.3M |
| Balance Sheet | |||||
| Cash and equivalents | $159.6M | $367.0M | $342.5M | $263.2M | $316.8M |
| Current assets | $376.3M | $596.0M | $596.8M | $605.3M | $681.5M |
| Total assets | $1.4B | $1.6B | $1.7B | $1.7B | $1.9B |
| Current liabilities | $88.3M | $301.2M | $96.3M | $89.9M | $87.2M |
| Total liabilities | $523.3M | $735.7M | $739.7M | $742.0M | $761.5M |
| Total debt | $345.0M | $546.2M | $538.2M | $535.4M | $533.7M |
| Stockholders' equity | $836.6M | $902.3M | $941.5M | $998.0M | $1.1B |
| Cash Flow Statement | |||||
| Cash from operations | $5.2M | $7.0M | -$2.0M | -$66.0M | -$26.7M |
| Depreciation and amortization | $36.1M | $39.1M | $37.5M | $35.4M | $30.2M |
| Stock-based compensation | $41.3M | $33.4M | $24.6M | $24.7M | $22.5M |
| Capital expenditure | $27.0M | $41.1M | $28.8M | $30.9M | $64.1M |
| Free cash flow | -$21.8M | -$34.0M | -$30.7M | -$96.9M | -$90.9M |
| Impairments | $3.5M | $0 | $0 | $718,000 | $0 |
Shares outstanding 130.2M · Free float 81.8%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.